03:11:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-06-12 X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-28 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2024-02-01 10:00:00

Anders Ljunggren will support Stuart Gander, who as previously communicated, will take over as Group CEO as of 1 March 2024. Anders Ljunggren will be based in Uppsala and thus work as a strong bridge between Uppsala and the US where Stuart Gander is initially based.

Anders Ljunggren has extensive experience from the healthcare industry, with a focus on diagnostics and medical technology. In recent years, he has led the project organization at Q-linea and has previously worked with, among others, Tobii and GE Healthcare. Anders has a deep knowledge of Q-linea's various departments and is a member of the company's management team.

"I am very much looking forward to starting to work with Stuart and continuing to work with the management team in my new role, with a focus on helping the organization develop to become even better at delivering its projects and commitments according to our strategic plan. Q-linea consists of a team of highly competent people and the work holds a high technical level. It is an environment that I have worked in for many years and feel comfortable in. I am grateful for the trust that the board has given me and am humbled by the challenge that the role of Managing Director entails", says Anders Ljunggren, incoming Managing Director of Q-linea AB.

"I welcome Anders in his new role as leader of Q-linea's Swedish organization. Together with Stuart and others in the management group, they will form a strong team for Q-linea's continued commercialization and development", says Erika Kjellberg Eriksson, Chairman of the board of Q-linea.